ReviewDiscover nano2026
Tissue derived extracellular vesicles advance from disease mechanisms to clinical application.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Extracellular vesicles (EVs), nanoscale membranous structures secreted by cells, have gradually evolved from being passive communication vehicles and could now contribute to the development of engineerable theranostic nanoplatforms. Among these, tissue-derived extracellular vesicles (Ti-EVs) have demonstrated the potential for higher yields and may better reflect the physiological or pathological state of the tissue microenvironment compared to cell-culture counterparts. These advantages may make Ti-EVs potentially valuable tools for studying disease mechanisms and developing targeted therapies. This review provides a comprehensive overview of Ti-EVs, including their isolation, characterization, and biological functions in various diseases. By summarizing the latest research and technological advances, we evaluate the potential of Ti-EVs to serve as modulators of disease progression, and discuss the challenges in their clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.